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Melanoma is the most aggressive of the common skin malignancies and is responsible for 75% of deaths from skin cancer.[1](#bjd18024-bib-0001){ref-type="ref"} The American Joint Committee of Cancer staging system gives a clear prognostic value for patients with melanoma but cannot explain individual differences in survival.[2](#bjd18024-bib-0002){ref-type="ref"}

Femaleness has been demonstrated to be an independent, favourable prognostic factor in cutaneous malignant melanoma across nearly all tumour stages, including thin invasive tumours and advanced melanomas.[3](#bjd18024-bib-0003){ref-type="ref"}, [4](#bjd18024-bib-0004){ref-type="ref"}, [5](#bjd18024-bib-0005){ref-type="ref"}, [6](#bjd18024-bib-0006){ref-type="ref"}, [7](#bjd18024-bib-0007){ref-type="ref"} Furthermore, males exhibit worse prognostic features, as they are more likely to have thick or ulcerated melanomas, and melanoma located on the trunk.[7](#bjd18024-bib-0007){ref-type="ref"}, [8](#bjd18024-bib-0008){ref-type="ref"}, [9](#bjd18024-bib-0009){ref-type="ref"} Moreover, recent data highlight differences in body mass index and interferon regulation between men and women that may differently affect antitumour responses to immunotherapy.[10](#bjd18024-bib-0010){ref-type="ref"}, [11](#bjd18024-bib-0011){ref-type="ref"}

Women have a higher prevalence of lighter hair colour and fairer skin than men.[12](#bjd18024-bib-0012){ref-type="ref"}, [13](#bjd18024-bib-0013){ref-type="ref"} The interaction between sex and genetic variants associated with tanning facility has been reported recently.[14](#bjd18024-bib-0014){ref-type="ref"}

*MC1R* is a highly polymorphic gene in the white population and one of the most important regulator genes in human skin and hair pigmentation.[15](#bjd18024-bib-0015){ref-type="ref"}, [16](#bjd18024-bib-0016){ref-type="ref"}, [17](#bjd18024-bib-0017){ref-type="ref"} *MC1R* variants have been classified as '*r*' variants when they have a low association with red hair colour phenotype (RHC) and '*R*' variants when they are highly associated with RHC.[18](#bjd18024-bib-0018){ref-type="ref"}, [19](#bjd18024-bib-0019){ref-type="ref"}, [20](#bjd18024-bib-0020){ref-type="ref"} Interestingly, *R* variants have been associated with fairer skin phenotypes in women.[21](#bjd18024-bib-0021){ref-type="ref"} Finally, inherited *MC1R* variants increase the risk of developing a primary melanoma,[22](#bjd18024-bib-0022){ref-type="ref"} yet appear to provide a survival advantage to these individuals.[23](#bjd18024-bib-0023){ref-type="ref"}, [24](#bjd18024-bib-0024){ref-type="ref"}, [25](#bjd18024-bib-0025){ref-type="ref"}

We hypothesized that inherited *MC1R* variants could play a differential role in survival in women and men.

Materials and methods {#bjd18024-sec-0007}
=====================

Cohort description {#bjd18024-sec-0008}
------------------

We used a cohort study design to analyse the prognostic value of germline *MC1R* status depending on sex in patients with melanoma. The cohort included 1341 consecutive patients with melanoma who were prospectively followed‐up in the Melanoma Unit of Hospital Clinic of Barcelona, between January 1996 and April 2018. All patients gave their written informed consent according to the Declaration of Helsinki, and the study was approved by the Research Ethics Committee of the Hospital Clinic of Barcelona (HCB/2015/0298 and HCB/2015/1032).

Clinical and phenotypic data from the patients and melanoma characteristics were collected in the Melanoma Unit database. For this study we extracted the basal demographic characteristics of the patients, clinical and pathological melanoma features, and survival outcome.

As inclusion criteria, only patients with a histopathological diagnosis of an invasive primary melanoma were considered for the study. For patients with multiple melanomas, the most invasive melanoma tumour by Breslow thickness was included, as it is the one that drives the prognosis.

Sentinel lymph node biopsy and follow‐up protocols were carried out according to the institution\'s guidelines.[26](#bjd18024-bib-0026){ref-type="ref"}, [27](#bjd18024-bib-0027){ref-type="ref"} Overall survival (OS) time was calculated from the date of diagnosis of the primary melanoma to the date of death by any cause or last follow‐up visit. Melanoma‐specific survival (MSS) was calculated from the time of diagnosis of the primary melanoma to the time of death by melanoma or the last follow‐up visit.

Our study was performed at a well‐known referral centre for advanced cases of melanoma, but bias may exist as it was a single‐centre study.

*MC1R* molecular screening {#bjd18024-sec-0009}
--------------------------

Genomic DNA was extracted from peripheral blood lymphocytes or saliva by standard methods. The whole coding region of *MC1R* was sequenced as reported elsewhere.[28](#bjd18024-bib-0028){ref-type="ref"}

Nonsynonymous *MC1R* variants were classified as RHC ('*R*') or non‐RHC ('*r*') according to previously reported criteria.[20](#bjd18024-bib-0020){ref-type="ref"}, [23](#bjd18024-bib-0023){ref-type="ref"}, [28](#bjd18024-bib-0028){ref-type="ref"} Therefore, the p.D84E, p.R142H, p.R151C, p.I155T, p.R160W and p.D294H *MC1R* variants were classified as '*R*', while all the other nonsynonymous *MC1R* variants were classified as '*r*'. Synonymous variants were considered as wild‐type (WT) *MC1R* alleles ('*w*'). According to this classification we determined the following genotypes: *R/R*,*R/r*,*R/w*,*r/r*,*r/w*,*w/w*.

Statistical analyses {#bjd18024-sec-0010}
--------------------

Pearson\'s χ^2^‐test, trend test for ordinal variables and the Kruskal--Wallis rank sum test were used to compare categorical, ordinal and continuous variables, respectively. Survival curves based on Kaplan--Meier methods were used to calculate survival outcomes and the log‐rank test was used for curve comparison.

We considered OS and MSS as the main variables. In order to better manage possible statistical multiplicity when considering two primary variables (OS and MSS), *P*‐values were considered statistically significant if *P* ≤ 0·025, following Bonferroni correction. If the described model produced probability values that reached significance, the following hierarchical stepwise process to reject the null hypotheses was followed: the interaction effect with sex was evaluated and, if this was significant at *P* \< 0·10 (the usual cut‐off for interaction effects), the analysis was stratified by sex.[29](#bjd18024-bib-0029){ref-type="ref"}, [30](#bjd18024-bib-0030){ref-type="ref"}

Furthermore, in the stratified analysis, univariate and multivariate Cox logistic regression analysis were performed to assess the influence of germline *MC1R* status in OS and MSS depending on sex, and to estimate the hazard ratio (HR) for each of the survival outcomes.

Statistical analyses were performed using the computing environment R and RStudio.[31](#bjd18024-bib-0031){ref-type="ref"}, [32](#bjd18024-bib-0032){ref-type="ref"}

Results {#bjd18024-sec-0011}
=======

A total of 3999 patients with a histopathological diagnosis of an invasive primary melanoma were identified. However, after applying the inclusion and exclusion criteria, 2658 patients were excluded, leaving 1341 eligible for inclusion (Fig. [1](#bjd18024-fig-0001){ref-type="fig"}). Total person‐months were 105 775 with an incidence rate of relapse of 2·72 cases per 1000 person‐months. Median follow‐up time was 63·5 months (interquartile range 31·5--115·9).

![Flowchart of the study cohort.](BJD-182-138-g001){#bjd18024-fig-0001}

The demographic, clinical and genetic characteristics of all included individuals are summarized in Table [1](#bjd18024-tbl-0001){ref-type="table"}, and the clinicopathological characteristics of all tumours are given in Table [2](#bjd18024-tbl-0002){ref-type="table"}. The average age of onset was 52·2 years in women and 56·7 years in men, and the mean Breslow thickness was 2·1 mm and 2·5 mm, respectively. Phenotypic characteristics showed a predominance of white skin, phototypes II and III, brown eyes and brown hair. Women had thinner tumours, which were less often ulcerated than those in men. Women presented more often with superficial spreading melanomas and tumours on the lower extremities. Men presented more often with nodular melanomas and tumours on the trunk.

###### 

Demographic, clinical and genetic characteristics of patients included at baseline

                               Women (*n* = 697)   Men (*n* = 644)   Total (*n* = 1341)   *P*‐value
  ---------------------------- ------------------- ----------------- -------------------- -----------
  Mean ± SD age of onset (y)   52·22 ± 18·12       56·68 ± 16·58     54·37 ± 17·53        \< 0·001
  Eye colour                                                                              \< 0·001
  Brown                        355 (56·5)          335 (58·6)        690 (57·5)           
  Green                        160 (25·5)          81 (14·2)         241 (20·1)           
  Blue                         98 (15·6)           138 (24·1)        236 (19·7)           
  Black                        13 (2·1)            11 (1·9)          24 (2·0)             
  Other                        2 (0·3)             7 (1·2)           9 (0·8)              
  Missing                      69                  72                141                  
  Hair colour                                                                             \< 0·001
  Brown                        419 (66·9)          328 (57·5)        747 (62·5)           
  Black                        29 (4·6)            64 (11·2)         93 (7·8)             
  Blonde                       138 (22·0)          150 (26·3)        288 (24·1)           
  Red                          40 (6·4)            28 (4·9)          68 (5·7)             
  Missing                      71                  74                145                  
  Ethnicity                                                                               0·620
  White                        629 (99·5)          574 (99·3)        1203 (99·4)          
  Latin                        1 (0·2)             2 (0·3)           3 (0·2)              
  Asian                        0 (0·0)             1 (0·2)           1 (0·1)              
  Black                        0 (0·0)             0 (0·0)           0 (0·0)              
  Other                        2 (0·3)             1 (0·2)           3 (0·2)              
  Missing                      65                  66                131                  
  Phototype                                                                               0·760
  I                            42 (6·6)            40 (6·8)          82 (6·7)             
  II                           328 (51·3)          301 (51·5)        629 (51·4)           
  III                          228 (35·7)          210 (35·9)        438 (35·8)           
  IV                           40 (6·3)            33 (5·6)          73 (6·0)             
  V                            1 (0·2)             1 (0·2)           2 (0·2)              
  Missing                      58                  59                117                  
  Naevus count                                                                            0·919
  0--50                        307 (54·0)          282 (53·6)        589 (53·8)           
  51--100                      149 (26·2)          143 (27·2)        292 (26·7)           
  ≥ 101                        113 (19·9)          101 (19·2)        214 (19·5)           
  Missing                      128                 118               246                  
  Number of melanomas                                                                     0·036
  Single                       549 (78·8)          476 (73·9)        1025 (76·4)          
  Multiple                     148 (21·2)          168 (26·1)        316 (23·6)           
  *MC1R* status                                                                           0·488
  Wild‐type                    215 (30·8)          210 (32·6)        425 (31·7)           
  Variants                     482 (69·2)          434 (67·4)        916 (68·3)           
  *MC1R* genotype                                                                         0·245
  *RR*                         34 (4·9)            31 (4·8)          65 (4·8)             
  *Rr*                         80 (11·5)           51 (7·9)          131 (9·8)            
  *Rw*                         116 (16·6)          121 (18·8)        237 (17·7)           
  *rr*                         58 (8·3)            44 (6·8)          102 (7·6)            
  *rw*                         194 (27·8)          187 (29·0)        381 (28·4)           
  *ww*                         215 (30·8)          210 (32·6)        425 (31·7)           

Data are *n* (%) unless otherwise indicated.
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###### 

Clinicopathological characteristics of the included tumours

                            Women (*n* = 697)   Men (*n* = 644)   Total (*n* = 1341)   *P*‐value
  ------------------------- ------------------- ----------------- -------------------- -----------
  Mean ± SD Breslow index   2·10 ± 3·27         2·47 ± 2·81       2·28 ± 3·06          \< 0·001
  Ulceration                                                                           \< 0·001
  Absent                    508 (80·6)          437 (72·2)        945 (76·5)           
  Present                   122 (19·4)          168 (27·8)        290 (23·5)           
  Missing                   67                  39                106                  
  Mean ± SD mitotic index   2·18 ± 3·95         2·53 ± 4·59       2·35 ± 4·28          0·122
  Missing                   133                 106               239                  
  Location                                                                             \< 0·001
  Trunk                     248 (38·2)          330 (54·1)        578 (45·9)           
  Lower limbs               184 (28·3)          78 (12·8)         262 (20·8)           
  Head and neck             69 (10·6)           95 (15·6)         164 (13·0)           
  Upper limbs               78 (12·0)           54 (8·9)          132 (10·5)           
  Acral                     50 (7·7)            48 (7·9)          98 (7·8)             
  Mucosa                    18 (2·8)            5 (0·8)           23 (1·8)             
  Other                     3 (0·5)             0 (0·0)           3 (0·2)              
  Missing                   47                  34                81                   
  Histological subtype                                                                 0·003
  Superficial spreading     459 (66·8)          397 (62·5)        856 (64·8)           
  Nodular                   99 (14·4)           105 (16·5)        204 (15·4)           
  Acral lentiginous         33 (4·8)            45 (7·1)          78 (5·9)             
  Lentiginous malignant     27 (3·9)            46 (7·2)          73 (5·5)             
  Other                     69 (10·0)           42 (6·6)          111 (8·4)            
  Missing                   10                  9                 19                   

Data are *n* (%) unless otherwise indicated.
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Considering that Breslow thickness and ulceration are two of the main prognostic factors in melanoma, we evaluated the association of *MC1R* genotype with these variables in our cohort. We saw no significant differences between *MC1R* WT individuals and *MC1R* variant carriers regarding Breslow index (*P* = 0·908). Similarly, no significant differences were detected between *MC1R* WT and *MC1R* variant carriers when stratified by ulceration (*P* = 0·309) (Table [S1](#bjd18024-sup-0001){ref-type="supplementary-material"}; see Supporting Information). Interestingly, the analysis was not statistically significant when stratified for female sex (Breslow index *P* = 0·895; ulceration *P* = 0·925).

Kaplan--Meier curves showed that men had lower OS rates than women (*P \<* 0·001; Fig. [2](#bjd18024-fig-0002){ref-type="fig"}). This worse prognosis in men was further confirmed in the analysis using the multivariate Cox logistic regression model \[HR 1·48, 95% confidence interval (CI) 1·15--1·91; *P =* 0·002\].

![Overall survival by sex.](BJD-182-138-g002){#bjd18024-fig-0002}

Analysis stratified by sex and *MC1R* genotype {#bjd18024-sec-0012}
----------------------------------------------

Kaplan--Meier curves were modelled for patients with *MC1R* status. We did not detect statistically significant differences in OS between *MC1R* WT patients and carriers of any *MC1R* variant (*P* = 0·24; Fig. [3](#bjd18024-fig-0003){ref-type="fig"}). Multivariate Cox regression analysis adjusted by sex, age, Breslow index and ulceration showed that *MC1R* genotype was not associated with better prognosis in this cohort (HR 0·88, 95% CI 0·68--1·14; *P* = 0·349).

![Overall survival by *MC1R* status depending on sex.](BJD-182-138-g003){#bjd18024-fig-0003}

We subsequently analysed the influence of sex on the effect of *MC1R* variants in survival. Kaplan--Meier curves showed that women with inherited *MC1R* variants had a better melanoma prognosis than those with *MC1R* WT (*P* \< 0·007). In contrast, the protective effect of inherited *MC1R* variants was not found in men (*P =* 0·35; Fig. [3](#bjd18024-fig-0003){ref-type="fig"}).

Subsequently, we evaluated the interaction effect of sex and *MC1R* status for OS (*P*‐value for interaction 0·004) and for MSS (*P*‐value for interaction 0·052), which were in both cases statistically significant at alpha (*P* \< 0·10), the usual measure of statistical significance for interaction effect. Consequently, we observed that the survival benefit derived from the *MC1R* mutational status depends on the sex of the patients.

Univariate Cox logistic regression analysis of OS and MSS in women showed that later age at onset, thicker tumours, high mitotic index and tumour ulceration were associated with a worse prognosis. By contrast, total naevus count \> 50 and the presence of inherited *MC1R* variants were protective. Multivariate Cox logistic regression analysis including 630 women confirmed that the presence of inherited *MC1R* variants was a protective factor for OS (HR 0·57, 95% CI 0·38--0·85; *P* = 0·006) and MSS (HR 0·49, 95% CI 0·29--0·81; *P* = 0·005) (Table [3](#bjd18024-tbl-0003){ref-type="table"}). After adjustment for other baseline characteristics (mitotic index, histological subtype and body site of the primary melanoma) the presence of any *MC1R* variation consistently showed a sizeable and statistical significance in HR estimation for OS and MSS.

###### 

Univariate and multivariate Cox regression analysis of overall survival (OS) and melanoma‐specific survival (MSS) in women

                                    OS                            MSS                                                         
  --------------------------------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  Inherited *MC1R* variants (yes)   0·57 (0·39--0·83, 0·003)      0·57 (0·38--0·85, 0·006)      0·53 (0·34--0·85, 0·008)      0·49 (0·29--0·81, 0·005)
  Age (continuous)                  1·06 (1·05--1·08, \< 0·001)   1·06 (1·05--1·08, \< 0·001)   1·04 (1·03--1·06, \< 0·001)   1·04 (1·02--1·05, \< 0·001)
  Breslow index (continuous)        1·06 (1·04--1·08, \< 0·001)   1·04 (1·01--1·06, 0·006)      1·06 (1·04--1·08, \< 0·001)   1·03 (1·00--1·07, 0·027)
  Ulceration (present)              3·71 (2·48--5·56, \< 0·001)   1·96 (1·27--3·01, 0·002)      4·83 (2·92--8·00, \< 0·001)   3·02 (1·76--5·18, \< 0·001)
  Mitotic index (continuous)        1·09 (1·06--1·13, \< 0·001)   --                            1·12 (1·08--1·16, \< 0·001)   --
  Naevus total count (\< 50)        --                            --                            --                            --
  51--100                           0·52 (0·29--0·92, 0·026)      --                            0·73 (0·38--1·39, 0·335)      --
  ≥ 101                             0·41 (0·21--0·81, 0·010)      --                            0·47 (0·21--1·07, 0·072)      --

HR, hazard ratio; CI, confidence interval. ^a^Multivariable analysis based on 630 women and 101 events (C‐index = 0·784); ^b^Multivariable analysis based on 630 women and 63 events (C‐index = 0·777)

John Wiley & Sons, Ltd

Similarly, univariate Cox logistic regression analysis in men showed that later age at onset, thicker tumours, the presence of ulceration and a high mitotic index were mortal risk factors, and a naevus total count \> 50 was a protective factor. Contrary to women, the presence of inherited *MC1R* variants was not associated with improved survival in men. Multivariate Cox logistic regression analysis including 605 men showed no effects on OS (HR 1·26, 95% CI 0·89--1·79; *P* = 0·185) or MSS (HR 1·09, 95% CI 0·71--1·67; *P* = 0·685) (Table [4](#bjd18024-tbl-0004){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analysis of overall survival (OS) and melanoma‐specific survival (MSS) in men

                                    OS                            MSS                                                         
  --------------------------------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  Inherited *MC1R* variants (yes)   1·17 (0·84--1·63, 0·347)      1·26 (0·89--1·79, 0·185)      0·98 (0·65--1·47, 0·917)      1·09 (0·71--1·67, 0·685)
  Age (continuous)                  1·05 (1·04--1·06, \< 0·001)   1·04 (1·03--1·05, \< 0·001)   1·02 (1·01--1·03, 0·001)      1·02 (1·00--1·03, 0·011)
  Breslow index (continuous)        1·18 (1·14--1·22, \< 0·001)   1·15 (1·10--1·20, \< 0·001)   1·21 (1·17--1·25, \< 0·001)   1·17 (1·12--1·23, \< 0·001)
  Ulceration (present)              2·75 (2·02--3·75, \< 0·001)   1·41 (0·97--2·06, 0·074)      3·55 (2·40--5·25, \< 0·001)   1·80 (1·13--2·88, 0·013)
  Mitotic index (continuous)        1·06 (1·03--1·08, \< 0·001)   --                            1·08 (1·05--1·11, \< 0·001)   --
  Naevus total count (\< 50)        --                            --                            --                            --
  51--100                           0·47 (0·28--0·77, 0·003)      --                            0·49 (0·26--0·93, 0·030)      --
  ≥ 101                             0·65 (0·40--1·06, 0·086)      --                            0·59 (0·30--1·15, 0·119)      --

HR, hazard ratio; CI, confidence interval. ^a^Multivariable analysis based on 605 men and 165 events (C‐index = 0·758). ^b^Multivariable analysis based on 605 men and 103 events (C‐index = 0·758)

John Wiley & Sons, Ltd

Discussion {#bjd18024-sec-0013}
==========

The significance of sex difference on melanoma prognosis is well known. Better MSS in women has been attributed to both lifestyle and biological factors. Women perform self‐examination or tend to contact dermatologists for screening more often than men, allowing an earlier diagnosis of melanoma in women.[33](#bjd18024-bib-0033){ref-type="ref"} Moreover, the survival prognosis is higher in women than in men throughout childbearing age, except during pregnancy. However, this survival benefit is not maintained after menopause. This suggests the importance of hormonal signalling in melanoma development.[34](#bjd18024-bib-0034){ref-type="ref"}, [35](#bjd18024-bib-0035){ref-type="ref"}, [36](#bjd18024-bib-0036){ref-type="ref"}

A BioGenoMEL collaborative study suggested that the presence of any inherited *MC1R* variants was associated with improved melanoma survival, adjusting for age and sex (HR 0·82, 95% CI 0·66--1·02; *P* = 0·08).[23](#bjd18024-bib-0023){ref-type="ref"} The result only reached statistical significance with the addition of the Leeds cohort data (HR 0·77, 95% CI 0·64--0·93; *P* = 0·005).[23](#bjd18024-bib-0023){ref-type="ref"} Taylor *et al*. also suggested that the presence of *MC1R* variants is associated with better MSS (but not OS) in individuals with a first incident primary melanoma.[25](#bjd18024-bib-0025){ref-type="ref"} These analyses did not stratify by sex and, consequently, this putative protective effect in women was not evaluated.

In our study we identified that inherited *MC1R* variants are associated with better survival in women but not in men. Additionally, we did not observe more severe pathological tumour characteristics in women with *MC1R* variants. Therefore, our study indicates, for the first time, that the presence of inherited *MC1R* variants may be an independent protective factor in the survival of female patients with melanoma. Although the sex‐related biological mechanisms that underlie this finding are unknown, we hypothesize that the regulation of oxidative stress could offer a partial explanation. In melanocytes, the loss of melanocortin 1 receptor (MC1R) function reduces DNA repair capacity and decreases antioxidant response,[37](#bjd18024-bib-0037){ref-type="ref"} causing genomic instability and increasing oxidative stress.[38](#bjd18024-bib-0038){ref-type="ref"} This may lead melanocytes to undergo malignant transformation. Interestingly, oestrogen (the primary female sex hormone) induces the generation of reactive oxidative species (ROS).[39](#bjd18024-bib-0039){ref-type="ref"} This fact is consistent with the higher incidence of melanoma in adult premenopausal women.[40](#bjd18024-bib-0040){ref-type="ref"} The effect of ROS on malignant cell transformation is dose dependent. While certain levels of ROS promote malignant transformation, excessively high ROS levels cause detrimental oxidative stress that can lead to cell death.[41](#bjd18024-bib-0041){ref-type="ref"} Therefore, we suggest that in women melanocytes harbouring *MC1R* variants could cause excessive oxidative damage that is detrimental to melanoma progression.

Previous studies have indicated that inherited *MC1R* variants contribute differently to pigmentation phenotype in men and women. Moreover, women carrying RHC *MC1R* variants tended to exhibit significantly fairer phototypes than men with the same *MC1R* genotypes.[42](#bjd18024-bib-0042){ref-type="ref"} Differences between the sexes according to *MC1R* status do not only affect pigmentation phenotype. A recently published study has shown that the risk of developing melanoma associated with inherited *MC1R* variants is much higher in women than in men.[43](#bjd18024-bib-0043){ref-type="ref"} In the same line, several studies have identified a sex‐differential effect of MC1R on analgesic response.[21](#bjd18024-bib-0021){ref-type="ref"}, [44](#bjd18024-bib-0044){ref-type="ref"} Specifically, women with two inherited *MC1R* variants show greater analgesia than men.[44](#bjd18024-bib-0044){ref-type="ref"} Taken together, these findings highlight the fact that MC1R is a pleiotropic protein involved in the regulation of different biological processes and show that some of these MC1R effects are sex dependent.

In conclusion, our results show that the presence of inherited *MC1R* variants improves survival in women with melanoma. This could explain some of the prognostic differences between men and women. Future prospective studies should take into account sex differences in survival and could help to explain how the inherited *MC1R* variants may play a role in survival. This could imply an improvement in personalized melanoma follow‐up.

Supporting information
======================

###### 

**Table S1** Analysis of clinicopathological characteristics according to *MC1R* genotype.

###### 

Click here for additional data file.
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